Biological Availability Clinical Trial
Official title:
A Single-arm Open-label Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults
Verified date | May 2022 |
Source | Gefion Canada Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The bioavailability of cannabinoids differs greatly for different routes of administration. When applied topically to the skin, they are absorbed through the skin or hair follicles while interacting with receptors to provide localized effects. To gain more information on the potential of this route of administration in therapeutic applications, this open-label study will investigate the skin absorption and bioavailability of CBD and THC delivered trans-dermally.
Status | Completed |
Enrollment | 18 |
Est. completion date | January 18, 2022 |
Est. primary completion date | January 18, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Healthy males and females between 25-65 years of age at screening 2. Body Mass Index (BMI) from 18.5 to 29.9 kg/m2, inclusive 3. Occasional users of cannabis: Have consumed cannabis products at least once in the past 6 months and at least 4 times in their lifetime but no more than 3 times per week and not within 48 hours of Visit 2 and have experienced psychotropic effects without severe adverse events (short term paranoia, belligerence, extreme hallucinations) requiring medical interventions. Eligibility will be determined on a case by case basis by the QI 4. Female participant is not of child bearing potential, which is defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have undergone natural menopause (have not had menses for > 1 year) OR Females of childbearing potential must agree to abstain from heterosexual intercourse or use two methods of contraception for 30 days prior to first treatment and for 30 days after the treatment. Subjects must have a negative urine pregnancy test result at screening and baseline. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: 1. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) 2. Double-barrier method 3. Intrauterine devices 4. Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) 5. Vasectomy of partner at least 6- months prior to screening 5. A male participant with sexual partners who are not pregnant or do not fit the criteria as indicated above in number 4 must meet the following criteria - Participant is unlikely to procreate, defined as surgically sterile (i.e. has undergone vasectomy, it must be at least 6 months since the surgery) - Participant agrees to use of the accepted contraceptive regimens from first drug administration until 30 days after the drug administration - An acceptable method of contraception includes one of the following: - Abstinence from heterosexual intercourse - Condom with spermicide 6. Agrees to avoid alcohol intake 48 h prior to visit 2 7. Agrees to avoid tobacco or nicotine-containing products 96 hours prior to visit 2 8. Healthy as determined by medical history and laboratory results, as assessed by the QI 9. Agrees to complete all study related procedures and assessments 10. Agrees to provide information of two adult contacts to be reached in the event of transportation requirements from the clinic to their home after the study visits 11. Provides voluntary, written informed consent to participate in the study Exclusion Criteria: 1. Women who are pregnant, breast feeding, or planning to become pregnant during the course of the trial 2. Allergy or sensitivity to investigational product's active or inactive ingredients 3. Acute or chronic skin disease (i.e. atopic dermatitis, eczema, rosacea, psoriasis) or dermatological conditions (open wounds, scars, sunburns, moles) in the proposed area of application that would interfere with the application and absorption of the test product 4. Shaving, waxing or laser hair removal of the planned study treatment application area within 14 days prior to baseline. Tattoos on the planned study application area. 5. Current use of prescribed medication containing the ingredients in the IP 6. Current use of over-the-counter medications, supplements, and foods/drinks containing the ingredients in the IP unless willing to washout 7. Prescribed or OTC medication, supplements, or food/drinks that will interact with the investigational product 8. Positive drug of abuse test at baseline 9. History of alcohol and/or drug abuse or substance dependence within the last 12 months 10. High alcohol intake (average of >2 standard drinks per day) 11. Self-reported serious psychological disorder(s) diagnosis e.g. schizophrenia, bipolar disorder, depression, PTSD, sleep disorder that, in the QI's opinion, could interfere with study participation. History of suicidal ideation, attempts and/or behaviour. 12. History of psychosis in immediate family including schizophrenia and affective psychosis 13. Cancer, except basal cell skin carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable 14. Major surgery in the past 3 months or individuals who have planned surgery during the course of the trial. Participants with minor surgery will be considered on a case-by-case basis by the QI 15. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI 16. Self-reported cardiovascular disease. Participants with no significant cardiovascular event in the past 1 year and who are on stable medication may be included after assessment by the QI on a case-by-case basis 17. Individuals with an autoimmune disease or who are immune-compromised 18. Positive laboratory results for HIV, Hepatitis B or C as assessed at screening 19. Type I or Type II diabetes 20. Current or history of significant liver disease or dysfunction that in the opinion of the QI may impact study outcomes or participant safety 21. History of or current diagnosis with kidney diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones symptom-free for 6 months 22. Self-reported current or pre-existing thyroid condition. Treatment on a stable dose medication for over 6 months will be reviewed on a case-by-case basis by the QI 23. Self- reported blood/bleeding disorder as assessed by the QI 24. Clinically significant abnormal laboratory results at screening as determined by the QI 25. Blood donation 30 days prior to screening, during the study, or a planned donation within 30-days of the last study visit 26. Participation in other clinical research trials 30 days prior to enrollment will be assessed on a case-by-case basis by the QI 27. Individuals who are unable to give informed consent 28. Any other condition or lifestyle factor, that, in the opinion of the QI may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant |
Country | Name | City | State |
---|---|---|---|
Canada | KGK Science Inc. | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Gefion Canada Inc. | KGK Science Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of pre-emergent and post-emergent adverse events (AEs) following a single dose of CBD and THC from GT4 technology | Number of pre-emergent and post-emergent adverse events will be determined to calculate the incidence. Adverse events will be recorded during the 12 h in-clinic visit and during a follow-up phone call (7 days) | 12-hour study period and follow-up call at 7 days | |
Other | Change in Aspartate Aminotransferase at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in Aspartate Aminotransferase at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in Alanine Aminotransferase at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in Alanine Aminotransferase at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in Alkaline Phosphatase at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline | Change in Alkaline Phosphatase at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in Total Bilirubin at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in Total Bilirubin at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in Creatinine at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in Creatinine at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in Estimated Glomerular Filtration Rate (eGFR) at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in eGFR at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in random glucose at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in random glucose at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in sodium levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in sodium levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in potassium levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in potassium levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in chloride levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in chloride levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in White Blood Cell Count (WBC) at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in WBC at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in amount of Neutrophils at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in amount of Neutrophils at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in amount of Lymphocytes at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in amount of Lymphocytes at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in amount of Monocytes at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in amount of Monocytes at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in amount of Eosinophils at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in amount of Eosinophils at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in amount of Basophils at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in amount of Basophils at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in Red Blood Cell Count (RBC) at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in Red Blood Cell Count (RBC) at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in hemoglobin levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in hemoglobin levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in hematocrit levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in hematocrit levels at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in platelet count at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in platelet count at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in Mean Corpuscular Volume (MCV) at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in MCV at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in mean corpuscular hemoglobin (MCH) at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in MCH at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in mean corpuscular hemoglobin concentration (MCHC) at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in MCHC at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Change in red cell distribution width (RDW) at 12-h post dose following acute topical administration using GT4 technology of CBD and THC compared to baseline. | Change in RDW at 12-h post dose following acute topical administration using GT4 technology of CBD and THC will be compared to baseline. | 12-hour study period | |
Other | Psychoactive Assessment following acute topical administration using GT4 technology of CBD and THC. | Psychoactive Assessment as administered at post-dose at 10, 20, 30, 45 min and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 h.
The "Psychoactive Assessment" will be administered just before each post-dose blood draw with the following questions: Are you experiencing a "high" feeling? On a scale of 1 (least) to 10 (most), how intense is that feeling? Is this "high" feeling (other than intensity) different than past high experiences? If yes, please describe. |
12-hour study period | |
Other | Area under the curve to the last measured timepoint (AUCT) for Cannabinol (CBN) metabolite following acute topical administration using GT4 technology of CBD and THC | The AUCT will be calculated using the trapezoid approximation. Time points assessed for AUC0-12 h: pre-dose (T = 0 h) and post-dose at 10, 20, 30, 45 min and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 h. | 12-hour study period | |
Other | Maximum concentration (Cmax) for Cannabinol (CBN) metabolite following acute topical administration using GT4 technology of CBD and THC | Peak concentration (Cmax) will be determined directly from the concentration-time curve. | 12-hour study period | |
Other | Time to maximum concentration (Tmax) for Cannabinol (CBN) metabolite following acute topical administration using GT4 technology of CBD and THC | Time to peak concentration (Tmax) will be determined directly from the concentration-time curve. | 12-hour study period | |
Other | Area under the curve to infinity (AUCI) for Cannabinol (CBN) metabolite following acute topical administration using GT4 technology of CBD and THC | The area under the curve to infinity AUCI will be calculated by AUCT + CT/ ?, where CT is the last quantifiable concentration. | 12-hour study period | |
Other | Terminal elimination rate constant (? or ke) for Cannabinol (CBN) metabolite following acute topical administration using GT4 technology of CBD and THC | Terminal disposition rate constant (?) will be calculated as the slope of points on the terminal log-linear end of the concentration versus time curve. | 12-hour study period | |
Other | Terminal half-life (t1/2) for Cannabinol (CBN) metabolite following acute topical administration using GT4 technology of CBD and THC | Terminal half-life (t1/2) will be calculated as ln(2)/? = 0.693/?. | 12-hour study period | |
Other | Absorption rate constant (ka) for for Cannabinol (CBN) metabolite following acute topical administration using GT4 technology of CBD and THC | The absorption rate constant (ka) will be calculated using the feathering method. | 12-hour study period | |
Primary | Area under the curve to the last measured timepoint (AUCT) for CBD metabolite following acute topical administration using GT4 technology of CBD and THC | The AUCT will be calculated using the trapezoid approximation. Time points assessed for AUC0-12 h: pre-dose (T = 0 h) and post-dose at 10, 20, 30, 45 min and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 h. | 12-hour study period | |
Primary | Area under the curve to the last measured timepoint (AUCT) for THC metabolite following acute topical administration using GT4 technology of CBD and THC | The AUCT will be calculated using the trapezoid approximation. Time points assessed for AUC0-12 h: pre-dose (T = 0 h) and post-dose at 10, 20, 30, 45 min and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 h. This parameter will be presented for each metabolite, for each study participant. | 12-hour study period | |
Primary | Maximum concentration (Cmax) for CBD metabolite following acute topical administration using GT4 technology of CBD and THC | Peak concentration (Cmax) will be determined directly from the concentration-time curve. | 12-hour study period | |
Primary | Maximum concentration (Cmax) for THC metabolite following acute topical administration using GT4 technology of CBD and THC | Peak concentration (Cmax) will be determined directly from the concentration-time curve. | 12-hour study period | |
Primary | Time to maximum concentration (Tmax) for CBD metabolite following acute topical administration using GT4 technology of CBD and THC | Time to peak concentration (Tmax) will be determined directly from the concentration-time curve. | 12-hour study period | |
Primary | Time to maximum concentration (Tmax) for THC metabolite following acute topical administration using GT4 technology of CBD and THC | Time to peak concentration (Tmax) will be determined directly from the concentration-time curve. | 12-hour study period | |
Primary | Area under the curve to infinity (AUCI) for CBD metabolite following acute topical administration using GT4 technology of CBD and THC | The area under the curve to infinity AUCI will be calculated by AUCT + CT/ ?, where CT is the last quantifiable concentration. | 12-hour study period | |
Primary | Area under the curve to infinity (AUCI) for THC metabolite following acute topical administration using GT4 technology of CBD and THC | The area under the curve to infinity AUCI will be calculated by AUCT + CT/ ?, where CT is the last quantifiable concentration. | 12-hour study period | |
Primary | Terminal elimination rate constant (? or ke) for CBD metabolite following acute topical administration using GT4 technology of CBD and THC | Terminal disposition rate constant (?) will be calculated as the slope of points on the terminal log-linear end of the concentration versus time curve. | 12-hour study period | |
Primary | Terminal elimination rate constant (? or ke) for THC metabolite following acute topical administration using GT4 technology of CBD and THC | Terminal disposition rate constant (?) will be calculated as the slope of points on the terminal log-linear end of the concentration versus time curve. | 12-hour study period | |
Primary | Terminal half-life (t1/2) for CBD metabolite following acute topical administration using GT4 technology of CBD and THC | Terminal half-life (t1/2) will be calculated as ln(2)/? = 0.693/?. | 12-hour study period | |
Primary | Terminal half-life (t1/2) for THC metabolite following acute topical administration using GT4 technology of CBD and THC | Terminal half-life (t1/2) will be calculated as ln(2)/? = 0.693/?. | 12-hour study period | |
Primary | Absorption rate constant (ka) for CBD metabolite following acute topical administration using GT4 technology of CBD and THC | The absorption rate constant (ka) will be calculated using the feathering method. | 12-hour study period | |
Primary | Absorption rate constant (ka) for THC metabolite following acute topical administration using GT4 technology of CBD and THC | The absorption rate constant (ka) will be calculated using the feathering method. | 12-hour study period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05544786 -
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
|
Phase 1 | |
Completed |
NCT04744233 -
Bioavailability of Carotenoids From Orange Juice in a Cross-over Study in Healthy Subjects.
|
N/A | |
Completed |
NCT05561075 -
Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form (BIOPTERO)
|
N/A | |
Completed |
NCT03873909 -
Bioavailability of Carotenoids Present in Mamey Sapote (Pouteria Sapota (Jacq.) H. E. Moore & Stearn) Fruit
|
N/A | |
Completed |
NCT03353857 -
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
|
Phase 1 | |
Completed |
NCT01267201 -
A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form
|
Phase 1 | |
Completed |
NCT02538393 -
Relative Bioavailability of Sorafenib Tablet for Oral Suspension
|
Phase 1 | |
Completed |
NCT05116982 -
Effect of Three Silicon Based Food Supplements on the Urinary Excretion of Aluminum and Other Metals (SILIAL)
|
N/A | |
Completed |
NCT04207372 -
Protein Digestibility of Whey and Zein.
|
N/A | |
Completed |
NCT01853800 -
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
|
Phase 1 | |
Completed |
NCT00714584 -
Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04876261 -
Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements
|
N/A | |
Completed |
NCT03886597 -
Nutritional Intervention With Table Olives in Healthy Volunteers
|
Phase 1/Phase 2 | |
Completed |
NCT06289140 -
Oral Bioavailability of a New Formulation of Pterostilbene Cocrystal in Comparison With Its Free Form (BIOPTERO2)
|
N/A | |
Completed |
NCT05439408 -
Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03951025 -
Study of the Bioavailability of a Food Supplement Rich in Melatonin Administered Sublingually and Orally (MELATONIN)
|
Phase 2 | |
Completed |
NCT03984916 -
Study of the Bioavailability of Three Hesperidin Extracts.
|
N/A | |
Completed |
NCT02966704 -
Stable Isotope Method to Assess Dietary Protein Quality
|
N/A | |
Completed |
NCT02847117 -
Bioavailability of the Microconstituents of Natural Chios Mastiha in Healthy Adults.
|
N/A | |
Completed |
NCT03048110 -
Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction
|
Phase 1 |